Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies
-
Hugo Vanderstichele
Abstract
Background: Total tau (T-tau) and β-amyloid(1-42) (Aβ1-42) levels in cerebrospinal fluid (CSF) can differentiate Alzheimer's disease (AD) from normal aging or depressive pseudo-dementia. Differential diagnosis from dementia with Lewy bodies (DLB) in clinical settings is difficult.
Methods: The analytical performance of the INNOTEST® PHOSPHO-TAU(181P) assay was validated in terms of selectivity, sensitivity, specificity, precision, robustness, and stability. Clinical utility of the assay alone, or combined with T-tau and Aβ1-42, for discrimination of AD (n=94) from patients suffering from DLB (n=60) or from age-matched control subjects (CS) (n=60) was assessed in a multicenter study.
Results: CSF concentrations of tau phosphorylated at threonine 181 (P-tau181P) in AD was significantly higher than in DLB and CS. Discriminant analysis, a classification tree, and logistic regression showed that P-tau181P was the most statistically significant single variable of the three biomarkers for discrimination between AD and DLB.
Conclusions: P-tau181P quantification is a robust and reliable assay that may be useful in discriminating AD from DLB.
Clin Chem Lab Med 2006;44:1472–80.
References
1. Wiltfang J, Esselman H, Maler JM, Bleich S, Hüther G, Kornhuber J. Molecular biology of Alzheimer's dementia and its clinical relevance to early diagnosis and new therapeutic strategies. Gerontology 2001; 47:65–71.10.1159/000052775Search in Google Scholar
2. Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 2000; 33:95–130.10.1016/S0165-0173(00)00019-9Search in Google Scholar
3. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2:605–13.10.1016/S1474-4422(03)00530-1Search in Google Scholar
4. Consensus report of the working group on molecular and biochemical markers of Alzheimer's disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19:109–16 (Erratum in Neurobiol Aging1998;19:285).10.1016/S0197-4580(98)00022-0Search in Google Scholar
5. Vanmechelen E, Van Kerschaver E, Blennow K, De Deyn PP, Galasko D, Parnetti L, et al. CSF-Phospho-tau (181P) as a promising marker for discriminating Alzheimer's disease from dementia with Lewy bodies. In: Iqbal K, Sisodia SS, Winblad B, editors. Alzheimer's disease: advances in etiology, pathogenesis and therapeutics. New York: Wiley, 2001;285–91.Search in Google Scholar
6. Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, van Kamp GJ, et al. Amyloid β(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 2004; 62:1580–4.10.1212/01.WNL.0000123249.58898.E0Search in Google Scholar
7. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989; 3:519–26.10.1016/0896-6273(89)90210-9Search in Google Scholar
8. Vandermeeren M, Mercken M, Vanmechelen E, Six J, Van de Voorde A, Martin J-J, et al. Detection of τ proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993; 61:1828–34.10.1111/j.1471-4159.1993.tb09823.xSearch in Google Scholar
9. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse M-A, Andreasen N, et al. Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 2000; 7:245–58.10.3109/13506120009146438Search in Google Scholar
10. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjögren M, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000; 285:49–52.10.1016/S0304-3940(00)01036-3Search in Google Scholar
11. ISO 5725–2: Accuracy (trueness and precision) of measurement methods and results - Part 2: Basic method for the determination of repeatability and reproducibility of a standard measurement method, Geneva: International Organization for Standardization, 1994.Search in Google Scholar
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939–44.10.1212/WNL.34.7.939Search in Google Scholar PubMed
13. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47:1113–24.10.1212/WNL.47.5.1113Search in Google Scholar
14. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189–98.10.1016/0022-3956(75)90026-6Search in Google Scholar
15. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF. Neurology 1999; 52:1555–62.10.1212/WNL.52.8.1555Search in Google Scholar
16. Goedert M, Jakes R, Crowther RA, Cohen P, Vanmechelen E, Vandermeeren M, et al. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem J 1994; 301:871–7.10.1042/bj3010871Search in Google Scholar PubMed PubMed Central
17. Sjögren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 70:624–30.10.1136/jnnp.70.5.624Search in Google Scholar PubMed PubMed Central
18. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of β-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP Technology. Clin Chem 2005; 51:336–45.10.1373/clinchem.2004.039347Search in Google Scholar PubMed
19. Mollenhauer B, Bibl M, Wiltfang J, Steinacker P, Ciesiel-czyk B, Neubert K, et al. Total tau protein, posphorylated tau (181p) protein, β-amyloid1-42, and β-amyloid1-40 in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin Chem Lab Med 2006; 44:192–5.10.1515/CCLM.2006.035Search in Google Scholar PubMed
20. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004; 1:213–25.10.1602/neurorx.1.2.213Search in Google Scholar PubMed PubMed Central
21. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 2004; 61:95–102.10.1001/archpsyc.61.1.95Search in Google Scholar PubMed
22. Buerger K, Ewers M, Andreasen N, Zinkowski R, Ishiguro K, Vanmechelen E, et al. Phosphorylated tau predicts rate of cognitive decline in MCI subjects – a comparative CSF study. Neurology 2005; 65:1502–3.10.1212/01.wnl.0000183284.92920.f2Search in Google Scholar PubMed
23. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002; 59:1267–72.10.1001/archneur.59.8.1267Search in Google Scholar
24. Nägga K, Gottfries J, Blennow K, Marcusson J. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord 2002; 14:183–90.10.1159/000066023Search in Google Scholar
25. Jimenez-Jimenez FJ, Hernanz A, Medina-Acebron S, de Bustos F, Zurdo JM, Alonso H, et al. Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2005; 111:114–7.10.1111/j.1600-0404.2005.00370.xSearch in Google Scholar
26. Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M, Wiltfang J, Kretzschmar H, et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry 2003; 8:343–7.10.1038/sj.mp.4001220Search in Google Scholar
27. Zetterberg H, Blennow K. Elevated total tau/phospho-tau ratio in autopsy-proven Creutzfeldt-Jakob disease with negative 14-3-3 test results. Neurol Sci 2004; 25:301–2.10.1007/s10072-004-0358-5Search in Google Scholar
28. Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, et al. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature. J Mol Neurosci 2004; 23:115–22.10.1385/JMN:23:1-2:115Search in Google Scholar
29. Maddalena A, Papassotiropoulos A, Müller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide42. Arch Neurol 2003; 60:1202–6.10.1001/archneur.60.9.1202Search in Google Scholar
30. Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B, et al. Tau protein, Aβ42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 2005; 19:164–70.10.1159/000083178Search in Google Scholar PubMed
©2006 by Walter de Gruyter Berlin New York
Articles in the same Issue
- Initiation and progression of atherosclerosis – enzymatic or oxidative modification of low-density lipoprotein?
- Blood transfusions in athletes. Old dogmas, new tricks
- Molecular detection of tyrosinase transcripts in peripheral blood from patients with malignant melanoma: correlation of PCR sensitivity threshold with clinical and pathologic disease characteristics
- Increase in and clearance of cell-free plasma DNA in hemodialysis quantified by real-time PCR
- Lipoprotein lipase gene polymorphism at the PvuII locus and serum lipid levels in Guangxi Hei Yi Zhuang and Han populations
- Interpretation of cardiac troponin T behaviour in size-exclusion chromatography
- Point-of-care C-reactive protein testing in febrile children in general practice
- Improvement in HPLC separation of porphyrin isomers and application to biochemical diagnosis of porphyrias
- Measurement of late-night salivary cortisol with an automated immunoassay system
- Combining markers of nephrotoxicity and hepatotoxicity for improved monitoring and detection of chronic alcohol abuse
- Stone or stricture as a cause of extrahepatic cholestasis – do liver function tests predict the diagnosis?
- Insulin resistance and enhanced protein glycation in men with prehypertension
- Prevalence-dependent decision limits for the early detection of type 2 diabetes mellitus in venous blood, venous plasma and capillary blood during glucose challenge
- Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies
- Variations in assay protocol for the Dako cystatin C method may change patient results by 50% without changing the results for controls
- Approved IFCC recommendation on reporting results for blood glucose: International Federation of Clinical Chemistry and Laboratory Medicine Scientific Division, Working Group on Selective Electrodes and Point-of-Care Testing (IFCC-SD-WG-SEPOCT)
- National survey on the pre-analytical variability in a representative cohort of Italian laboratories
- 10% CV concentration for the fourth generation Roche cardiac troponin T assay derived from Internal Quality Control data
- Biological variation of non-SI traceable biological quantities: example of proteins
- Effect of tibolone therapy on lipids and coagulation indices
- Acknowledgement
- Contents Volume 44, 2006
- Author Index
- Subject Index
Articles in the same Issue
- Initiation and progression of atherosclerosis – enzymatic or oxidative modification of low-density lipoprotein?
- Blood transfusions in athletes. Old dogmas, new tricks
- Molecular detection of tyrosinase transcripts in peripheral blood from patients with malignant melanoma: correlation of PCR sensitivity threshold with clinical and pathologic disease characteristics
- Increase in and clearance of cell-free plasma DNA in hemodialysis quantified by real-time PCR
- Lipoprotein lipase gene polymorphism at the PvuII locus and serum lipid levels in Guangxi Hei Yi Zhuang and Han populations
- Interpretation of cardiac troponin T behaviour in size-exclusion chromatography
- Point-of-care C-reactive protein testing in febrile children in general practice
- Improvement in HPLC separation of porphyrin isomers and application to biochemical diagnosis of porphyrias
- Measurement of late-night salivary cortisol with an automated immunoassay system
- Combining markers of nephrotoxicity and hepatotoxicity for improved monitoring and detection of chronic alcohol abuse
- Stone or stricture as a cause of extrahepatic cholestasis – do liver function tests predict the diagnosis?
- Insulin resistance and enhanced protein glycation in men with prehypertension
- Prevalence-dependent decision limits for the early detection of type 2 diabetes mellitus in venous blood, venous plasma and capillary blood during glucose challenge
- Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies
- Variations in assay protocol for the Dako cystatin C method may change patient results by 50% without changing the results for controls
- Approved IFCC recommendation on reporting results for blood glucose: International Federation of Clinical Chemistry and Laboratory Medicine Scientific Division, Working Group on Selective Electrodes and Point-of-Care Testing (IFCC-SD-WG-SEPOCT)
- National survey on the pre-analytical variability in a representative cohort of Italian laboratories
- 10% CV concentration for the fourth generation Roche cardiac troponin T assay derived from Internal Quality Control data
- Biological variation of non-SI traceable biological quantities: example of proteins
- Effect of tibolone therapy on lipids and coagulation indices
- Acknowledgement
- Contents Volume 44, 2006
- Author Index
- Subject Index
